Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cord blood cells aim to speed platelet recovery in transplant patients

NCT ID NCT07696767

Disease control Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early study tests an experimental cell therapy called MegaLT, made from umbilical cord blood cells, to help restore platelet levels faster after a cord blood transplant. Adults with blood cancers who receive a cord blood transplant will get a single infusion of MegaLT two weeks later. The goal is to see if it safely reduces the time to platelet recovery and the need for platelet transfusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MegaLT Injection (megakaryocyte cell product from cord blood)
What this could lead to
If it works, this could reduce the time patients need platelet transfusions after a cord blood transplant, lowering infection and bleeding risks.
What could go wrong
This is a very early, small study (7 people) testing safety and feasibility. It may not show clear benefit, and there could be infusion reactions or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 7 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years, male or female. * Patients with a definite diagnosis of hematologic malignancy who are undergoing umbilical cord blood transplantation. * Patients at day 14 after umbilical cord blood transplantation. * ECOG performance status ≤2. * Patients who voluntarily agree to participate in this clinical trial, fully understand the study content, and sign the informed consent form. Exclusion Criteria: * Patients with relapse of any malignant tumor. * Pregnant or lactating women. * Patients with severe infection or severe cardiac, hepatic, pulmonary, renal, neurologic, or metabolic disease. * Patients with a history of severe thrombotic events or known risk factors for thrombosis. Exception: participants for whom the investigator determines that the potential benefit of study participation outweighs the potential risk of thromboembolic events. * Patients with uncontrolled infectious disease or other serious diseases, including but not limited to infection such as HIV positivity, congestive heart failure, unstable angina, cardiac arrhythmia, psychosis, social circumstances that would limit compliance with study requirements, or any condition that the treating physician considers may pose unpredictable risks. * Patients with active hepatitis B or hepatitis C. * Patients who have previously received organ transplantation or are planning to receive organ transplantation, except for hematopoietic stem cell transplantation. * Patients who participated in another clinical study and used any investigational drug or device within 30 days before the baseline visit. Participation in observational studies is allowed. * Patients considered by the investigator to be unsuitable for participation in this clinical trial for any other reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignacies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignacies Platelet recovery after umbilical cord blood transplantation Thrombocytopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.